Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

141. A systematic review of pharmacological pain management in multiple sclerosis

A systematic review of pharmacological pain management in multiple sclerosis A systematic review of pharmacological pain management in multiple sclerosis A systematic review of pharmacological pain management in multiple sclerosis Jawahar R, Oh U, Yang S, Lapane KL CRD summary This review concluded that anticonvulsants and off-label use of dextromethorphan/quinidine were identified as promising treatments for chronic pain in multiple sclerosis but that the evidence was insufficient to establish (...) how to choose optimal therapy for particular patients. Limitations of the evidence and reporting in the review mean that the conclusions regarding anticonvulsants and dextromethorphan/quinidine may not be reliable; the part of the conclusion regarding optimal therapy appears appropriate because it reflects the paucity of the evidence presented. Authors' objectives To review pain management strategies for the reduction of non-spastic and non-trigeminal neuralgic pain in multiple sclerosis patients

DARE.2014

143. Mycophenolate mofetil for relapsing-remitting multiple sclerosis.

Mycophenolate mofetil for relapsing-remitting multiple sclerosis. BACKGROUND: Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system and a leading cause of disability in young and middle-aged adults. Mycophenolate mofetil (MMF) is an immunosuppressive agent that has been used for the prevention of allograft rejection after renal, cardiac, or liver transplant and in patients with autoimmune diseases such as active relapsing-remitting (RRMS) and progressive MS (...) . OBJECTIVES: To assess the efficacy and safety of MMF for preventing disease activity in patients with RRMS. SEARCH METHODS: We searched the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group Specialised Register (January 14, 2013). We searched three Chinese databases (January 2013) and checked reference lists of identified trials. We contacted authors and pharmaceutical companies to ask for additional information. We applied no language restrictions. SELECTION CRITERIA: We

Cochrane2014

144. Treatment of patients with multiple sclerosis: a review of guidelines

Treatment of patients with multiple sclerosis: a review of guidelines Treatment of patients with multiple sclerosis: a review of guidelines Treatment of patients with multiple sclerosis: a review of guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Treatment of patients with multiple sclerosis: a review of guidelines (...) . Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013 Authors' conclusions Limited evidence-based guidelines are available for the treatment of multiple sclerosis, and the stopping or switching of treatment. The available evidence has suggested plasmapheresis as an adjunctive or alternative treatment for MS, corticosteroids for the treatment of relapse, and natalizumab in cases of failure on other drugs or intolerance. Final

Health Technology Assessment (HTA) Database.2014

145. An RCT to treat learning impairment in multiple sclerosis: The MEMREHAB trial

An RCT to treat learning impairment in multiple sclerosis: The MEMREHAB trial 24212393 2013 12 10 2014 02 10 2017 02 20 1526-632X 81 24 2013 Dec 10 Neurology Neurology An RCT to treat learning impairment in multiple sclerosis: The MEMREHAB trial. 2066-72 10.1212/01.wnl.0000437295.97946.a8 To examine the efficacy of the modified Story Memory Technique (mSMT), a 10-session behavioral intervention teaching context and imagery to facilitate learning, to improve learning and memory abilities (...) in persons with multiple sclerosis (MS). This double-blind, placebo-controlled, randomized clinical trial included 86 participants with clinically definite MS, 41 in the treatment group and 45 in the placebo control group. Participants completed a baseline neuropsychological assessment, including questionnaires assessing everyday memory, a repeat assessment immediately posttreatment, and a long-term follow-up assessment 6 months after treatment. After completion of the treatment phase, persons

EvidenceUpdates2014 Full Text: Link to full Text with Trip Pro

146. Clinical review report. Teriflunomide (Aubagio ? Genzyme Canada) indication: relapsing-remitting multiple sclerosis

Clinical review report. Teriflunomide (Aubagio ? Genzyme Canada) indication: relapsing-remitting multiple sclerosis Clinical review report. Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis Clinical review report. Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation CADTH. Clinical review report. Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Clinical Review Report; SR0350. 2014 Authors' conclusions Based on the results of two phase 3 double-blind randomized controlled trials, teriflunomide 14 mg may reduce the annualized relapse rate (ARR) by approximately 30% to 35% compared

Health Technology Assessment (HTA) Database.2014

147. Teriflunomide (Aubagio ? Genzyme Canada) indication: relapsing-remitting multiple sclerosis

Teriflunomide (Aubagio ? Genzyme Canada) indication: relapsing-remitting multiple sclerosis Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH (...) . Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC Final Recommendation; SR0350. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that teriflunomide not be listed at the submitted price. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Administration, Oral; Canada; Crotonates; Drug Evaluation; Immunologic Factors; Multiple Sclerosis

Health Technology Assessment (HTA) Database.2014

148. Teriflunomide for treating relapsingûremitting multiple sclerosis (TA303)

Teriflunomide for treating relapsingûremitting multiple sclerosis (TA303) Teriflunomide for treating relapsing–remitting multiple sclerosis | Guidance and guidelines | NICE Teriflunomide for treating relapsing–remitting multiple sclerosis Technology appraisal guidance [TA303] Published date: 22 January 2014 Last updated: 01 June 2014 Share Guidance is recommended as a possible treatment for adults with that isn’t relapsing-remitting multiple sclerosis. What does this mean for me? If you have (...) active relapsing-remitting multiple sclerosis, and your doctor thinks that teriflunomide is the right treatment, you should be able to have the treatment on the NHS. Teriflunomide should be available on the NHS within 3 months of the guidance being issued. If you are not eligible for treatment as described above, you should be able to continue taking teriflunomide until you and your doctor decide it is the right time to stop. Your responsibility The recommendations in this guidance represent the view

National Institute for Health and Clinical Excellence - Technology Appraisals2014

149. Alemtuzumab for treating relapsing-remitting multiple sclerosis (TA312)

Alemtuzumab for treating relapsing-remitting multiple sclerosis (TA312) Alemtuzumab for treating relapsing‑remitting multiple sclerosis | Guidance and guidelines | NICE Alemtuzumab for treating relapsing‑remitting multiple sclerosis Technology appraisal guidance [TA312] Published date: 28 May 2014 Share Guidance on alemtuzumab (Lemtrada) for treating relapsing–remitting multiple sclerosis in adults. Guidance development process Next review: We will decide whether to review this guidance when

National Institute for Health and Clinical Excellence - Technology Appraisals2014

150. Pharmacoeconomic review report. Teriflunomide (Aubagio ? Genzyme Canada) indication: relapsing-remitting multiple sclerosis

Pharmacoeconomic review report. Teriflunomide (Aubagio ? Genzyme Canada) indication: relapsing-remitting multiple sclerosis Pharmacoeconomic review report. Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis Pharmacoeconomic review report. Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Pharmacoeconomic review report. Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Pharmacoeconomic Review Report; SR0350. 2014 Authors' conclusions CDR found several limitations with the manufacturer's economic analysis. A reanalysis addressing all of these limitations (except treatment waning

Health Technology Assessment (HTA) Database.2014

151. Effects of Reduced-fat Diet in Combination with Omega-3 Fatty Acid Supplementation on Exacerbations of Multiple Sclerosis

Effects of Reduced-fat Diet in Combination with Omega-3 Fatty Acid Supplementation on Exacerbations of Multiple Sclerosis "Effects of Reduced-fat Diet in Combination with Omega-3 Fatty Acid Sup" by Brooke A. Barnes < > > > > > Off-campus Pacific University users: To download campus access theses and dissertations, please with your PUNet ID and password. Non-Pacific University users: Please talk to your librarian about requesting this thesis or dissertation through interlibrary loan. Theses (...) or dissertations that have a specific embargo period indicated below will not be available to anyone until the date indicated. Title Author Date of Award Summer 8-9-2014 Degree Type Capstone Project (On-Campus Access Only) Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Multiple sclerosis (MS) is a chronic disabling disease which affects over 2.5 million people in the world and approximately 500 000 people in the United States. MS is an inflammatory demyelinating

Pacific University EBM Capstone Project2014

153. Plegridy (peginterferon beta-1a) - For the treatment of patients with relapsing forms of multiple sclerosis

Plegridy (peginterferon beta-1a) - For the treatment of patients with relapsing forms of multiple sclerosis Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Plegridy (peginterferon beta-1a) prefilled syringe and Plegridy Pen (peginterferon beta-1a) prefilled pen Company: Biogen Idec, Inc. Application No.: 125499 Approval Date: 8/15/2014 Persons with disabilities having problems accessing

FDA - Drug Approval Package2014

154. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. 24655729 2014 06 30 2014 07 09 2016 11 22 1474-547X 383 9936 2014 Jun 28 Lancet (London, England) Lancet Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. 2213-21 10.1016/S0140-6736(13)62242-4 S0140-6736(13)62242 (...) -4 Secondary progressive multiple sclerosis, for which no satisfactory treatment presently exists, accounts for most of the disability in patients with multiple sclerosis. Simvastatin, which is widely used for treatment of vascular disease, with its excellent safety profile, has immunomodulatory and neuroprotective properties that could make it an appealing candidate drug for patients with secondary progressive multiple sclerosis. We undertook a double-blind, controlled trial between Jan 28, 2008

Lancet2014

155. Complementary and alternative medicine in multiple sclerosis

Complementary and alternative medicine in multiple sclerosis Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis | Neurology Advertisement Search for this keyword Main menu User menu Search Search for this keyword The most widely read and highly cited peer-reviewed neurology journal Share March 25, 2014 ; 82 (12) Special Article Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis Report of the Guideline (...) , Portland; MS Center of Excellence–East (C.B.), VA Maryland Health Care System and Department of Neurology (C.B.), University of Maryland School of Medicine, Baltimore; Multiple Sclerosis Center (J.B.), Swedish Neuroscience Institute, Seattle, WA; Multiple Sclerosis Service and Complementary and Alternative Medicine Service (A.B.), Colorado Neurological Institute, Englewood; The Jacobs Neurological Institute (B.W.-G.), Buffalo, NY; Department of Neurology (G.S.G.), University of Kansas Medical Center

American Academy of Neurology2014

156. Assessment and management of psychiatric disorders in individuals with multiple sclerosis

Assessment and management of psychiatric disorders in individuals with multiple sclerosis Evidence-based guideline: Assessment and management of psychiatric disorders in individuals with MS | Neurology Advertisement Search for this keyword Main menu User menu Search Search for this keyword The most widely read and highly cited peer-reviewed neurology journal Share January 14, 2014 ; 82 (2) Special Article Evidence-based guideline: Assessment and management of psychiatric disorders (...) in individuals with MS Report of the Guideline Development Subcommittee of the American Academy of Neurology Sarah L. Minden , Anthony Feinstein , Rosalind C. Kalb , Deborah Miller , David C. Mohr , Scott B. Patten , Christopher Bever , Randolph B. Schiffer , Gary S. Gronseth and Pushpa Narayanaswami First published December 27, 2013, DOI: https://doi.org/10.1212/WNL.0000000000000013 Sarah L. Minden From the Department of Psychiatry, Brigham and Women's Hospital (S.L.M.), and Department of Neurology, Beth

American Academy of Neurology2014

158. Daclizumab for relapsing remitting multiple sclerosis.

Daclizumab for relapsing remitting multiple sclerosis. BACKGROUND: Monoclonal antibodies such as daclizumab could be a possible alternative immunotherapy to interferon beta treatment in people with multiple sclerosis (MS). It blocks the interleukin-2 receptor alpha subunit (CD25), and seems to be beneficial to patients with relapsing remitting multiple sclerosis (RRMS) in clinical and magnetic resonance imaging (MRI) measures of outcomes.This is an update of a Cochrane review first published (...) in 2010, and previously updated in 2012. OBJECTIVES: To assess the safety of daclizumab and its efficacy to prevent clinical worsening in patients with RRMS. SEARCH METHODS: The Trials Search Co-ordinator searched the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group Specialised Register (17 May 2013). We handsearched the references quoted in the identified trials and reports (May 2013) from the most important neurological associations and MS societies. We contacted

Cochrane2013

159. Pharmacological treatment for memory disorder in multiple sclerosis.

Pharmacological treatment for memory disorder in multiple sclerosis. BACKGROUND: This is an update of the Cochrane review "Pharmacologic treatment for memory disorder in multiple sclerosis" (first published in The Cochrane Library 2011, Issue 10).Multiple sclerosis (MS) is a chronic immune-mediated, inflammatory, demyelinating, neurodegenerative disorder of the central nervous system (CNS) and can cause both neurological and neuropsychological disability. Both demyelination and axonal (...) and neuronal loss are believed to contribute to MS-related cognitive impairment. Memory disorder is one of the most frequent cognitive dysfunctions and presents a considerable burden to people with MS and to society due to the negative impact on function. A number of pharmacological agents have been evaluated in many existing randomised controlled trials for their efficacy on memory disorder in people with MS but the results were not consistent. OBJECTIVES: To assess the absolute and comparative efficacy

Cochrane2013

160. Rituximab for relapsing-remitting multiple sclerosis.

Rituximab for relapsing-remitting multiple sclerosis. BACKGROUND: This is an update of the Cochrane review "Rituximab for relapsing-remitting multiple sclerosis" (first published in The Cochrane Library 2011, Issue 12).More than 80% of individuals with multiple sclerosis (MS) experience a relapsing-remitting disease course. Approximately 10 years after disease onset, an estimated 50% of individuals with relapsing-remitting MS (RRMS) convert to secondary progressive MS. MS causes a major (...) socioeconomic burden for the individual patient and for society. Effective treatment that reduces relapse frequency and prevents progression could impact both costs and quality of life and help to reduce the socioeconomic burden of MS. Alternative and more effective MS treatments with new modes of action and good safety are needed to expand the current treatment repertoire. It has been shown that B lymphocytes are involved in the pathophysiology of MS and rituximab lyses B-cells via complement-dependent

Cochrane2013